INDOCO2024-04-012024-06-30 INDOCO2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member INDOCO2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member INDOCO2024-06-30 INDOCO2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2024-04-01 2025-03-31 2024-07-23 2024-07-10 INR Lakhs First quarter 10:00:00 11:00:00 2024-07-23 2024-07-23 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 4314900000.00 10300000.00 4325200000.00 1062400000.00 362300000.00 -9800000.00 972600000.00 143100000.00 275200000.00 1449700000.00 4255500000.00 69700000.00 0.00 69700000.00 48100000.00 3400000.00 51500000.00 0.00 18200000.00 0.00 0.00 0.00 0.00 18200000.00 -800000.00 17400000.00 26200000.00 -8100000.00 25400000.00 -8100000.00 184400000.00 2 0.20 0.20 0.00 0.00 0.20 0.20 1. The unaudited Consolidated Results for the Quarter ended 30th June, 2024, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 23rd July, 2024. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Qtr ended Qtr ended Qtr ended Year ended & Income 30-06-2024 31-03-2024 30-06-2023 31-03-2024 from Operations (Unaudited) (Audited) (Unaudited) (Audited) India 25,675 22,451 23,417 96,758 Outside India 16,754 21,457 18,264 82,064 ---------------------------------------------------------------------------------------------------------------- Total : 42,429 43,908 41,681 1,78,822============================================================== 5. The Consolidated Financial Results includes the results of the following companies. ----------------------------------------------------------------------------------------------------------------------------- Name of the Company % of shareholding Consolidated as ------------------------------------------------------------------------------------------------------------------------------ XTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY & ENGINEERS PVT LTD INDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY INDOCO REMEDIES UK LTD 100.00 SUBSIDIARY WARREN REMEDIES PVT LTD 100.00 SUBSIDIARY FPP HOLDING COMPANY ,LLC 85.00 SUBSIDIARY -------------------------------------------------------------------------------------------------------------------------- 6. Figures for the quarter ended 31.3.2024 and 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2023 (limited reviewed) and 31.12.2022 (limited reviewed). 7. (*) Exceptional items include consideration received Rs. 19.7 cr for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Other Expenses 1202800000.00 Research & Development Expenses 246900000.00 Items that will not be reclassified to profit & loss -3000000.00 -3000000.00 -800000.00 Items that may be reclassified to profit or loss 1400000.00 1400000.00 0.00